An expert discusses the evolving landscape of large B-cell lymphoma (LBCL) treatment, highlighting emerging CAR T-cell targets and bispecific antibody strategies, the potential shift toward more ...

The NCCN added critical guidance on Lambert-Eaton myasthenic syndrome to its recommendation for the diagnosis and treatment ...

Medical practices face staffing shortages and rising costs, prompting innovative strategies for health benefits to enhance ...

Discover the latest breakthroughs in oncology, including FDA approvals and innovative therapies reshaping cancer treatment ...

Precision medicine revolutionizes cancer care, empowering patients with personalized insights and targeted therapies while ...

Jason Hammonds is the chief operating officer of oncology and specialty at McKesson.

Zanidatamab demonstrates an impressive 41% response rate and a 1-year duration of response in a large phase 2 BTC trial, offering a promising new option.

Zongertinib gains FDA approval for advanced NSCLC with HER2 mutations, showcasing promising efficacy and safety in clinical ...

ProteinQure's PQ203, a novel peptide drug conjugate, gains FDA fast track designation for advanced triple-negative breast ...

Zanidatamab, a bispecific HER2 antibody, shows promise in biliary tract cancer by requiring high HER2 expression and cross-linking receptors for efficacy.

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking ...

A study reveals real-world outcomes of neoadjuvant immune checkpoint inhibitors in nonmetastatic colon cancer, highlighting ...